TrovaGene, Inc. (TROV) News
Filter TROV News Items
TROV News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest TROV News From Around the Web
Below are the latest news stories about Trovagene Inc that investors may wish to consider to help them evaluate TROV as an investment opportunity.
Trovagene Announces First Quarter 2020 Results and HighlightsTrovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal cancer, prostate cancer and leukemia, today announced company highlights and financial results for the first quarter ended March 31, 2020. The company is issuing this press release in lieu of conducting a conference call. |
Trovagene Announces Changing of Company Name to Cardiff Oncology and Appointment of Mark Erlander, PhD, as Chief Executive OfficerSAN DIEGO, May 6, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing its drug, onvansertib, to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, Zytiga®-resistant… |
Trovagene Announces Fourth Quarter and Full-Year 2019 ResultsSAN DIEGO, Feb. 27, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including prostate, colorectal and leukemia, today… |
Trovagene Receives Approximately $1.45 Million From Exercise of WarrantsSAN DIEGO, Jan. 29, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including prostate, colorectal and leukemia,… |
Efficacy, Durability of Response and Safety of Onvansertib Demonstrated in Completed Phase 1b Trial in AML Patients Presented in Oral Session at ASHSAN DIEGO, Dec. 9, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, prostate and colorectal, today… |
Trovagene Announces $5.0 Million Private Placement Priced At-the-MarketSAN DIEGO, Oct. 25, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing… |
Trovagene's Onvansertib Shows Response in Phase Ib AML StudyTrovagene (TROV) successfully completes a phase Ib study, evaluating onvansertib in combination with standard-of-care in AML patients. The regimen is well tolerated and safe. |
TrovaGene, Inc. (NASDAQ:TROV) - TrovaGene Shares Volatile Ahead of Oncology PresentationTrovaGene Inc (NASDAQ: TROV) shares, which had been on a downtrend since early April, reversed course in mid-August. From an intraday low of $1.30 on … |
Trovagene Commences Non-Deal Investor RoadshowSAN DIEGO, July 15, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ company, developing targeted therapies to treat cancers with significant medical need for new treatment options, is pleased to release to shareholders and investors its latest Company |
The Daily Biotech Pulse: Roche Presents Positive Hemlibra Data, Amgen's Tender Offer For Nuevolution Complete, Genmab OfferingHere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 8) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Inspire Medical Systems Inc (NYSE: INSP ) (announced UnitedHealth Group Inc (NYSE: UNH ) coverage for Inspire therapy for the treatment of obstructive sleep apnea) Sol Gel Technologies Ltd (NASDAQ: SLGL )( reported positive results for late-stage trials that evaluated its Epsolay microencapsulated benzoyl peroxide cream, 5%, in papulopustular rosacea. Down In The Dumps (Biotech stocks hitting 52-week lows on July 8) Advaxis, Inc. (NASDAQ: ADXS ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Evolent Health Inc (NYSE: EVH ) Foamix Pharmaceuticals Ltd (NASDAQ: FO... |